• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » University of Cambridge, Genomics England, Illumina collaborate

University of Cambridge, Genomics England, Illumina collaborate

October 21, 2013
CenterWatch Staff

University of Cambridge, Genomics England and Illumina have announced the launch of a three-year project to sequence 10,000 whole genomes of children and adults with rare genetic diseases. The project is a pilot for Genomics England, which will provide 2,000 samples, and marks the beginning of the national endeavor to sequence 100,000 genomes in the U.K. National Health Service (NHS).

“This project will bring enormous improvements to the care of patients with rare genetic diseases. It will shorten the gap between the first signs of ill-health in a person and providing a conclusive diagnosis by using the power of modern DNA sequencing methods,” said Dr. John Bradley, director of the NIHR Cambridge Biomedical Research Center, a partnership between the University of Cambridge and Cambridge University Hospitals.

Most patients with a rare genetic disease go through a diagnostic odyssey to find the cause. For many, the long search is unsuccessful, which not only prevents the delivery of optimal care, but also may aggravate the condition. To improve patient care in the U.K., the University of Cambridge will work with the team led by Bentley, who also is vice president and chief scientist for Illumina, to develop the workflow and processes to bring routine clinical whole genome sequencing to the bedside.

Illumina will deliver whole genome sequence data for the project using technology invented in Cambridge. “In 1997, sequencing a person’s entire genome as part of healthcare was just an idea, and it has always been my hope that one day it would turn into reality and benefit thousands of patients,” said Shankar Balasubramanian, professor of chemistry at Cambridge University and inventor of the sequencing by synthesis technique that is used by Illumina’s instruments to read the DNA code.

“We are excited to be partnering in this ground-breaking project to discover the genes underlying rare genetic diseases, which may lead to offering new tests and pave the way for new opportunities for treatment,” said professor Mark Caulfield, Genomics England's chief scientist.

There are an estimated 7,000 rare diseases and about 3.5 million people in the U.K. will be affected by a rare disease at some point in their lives.

Sarah-Jane Marsh, chief executive at Birmingham Children’s Hospital, said, "More than 5% of babies are born with a genetic disease. At the moment, too many of the affected families are unable to access the best diagnostics and treatment available.”

The Rare Diseases Genomes Project will help to address this gap. The cumulative knowledge which will be gained from collecting this data will improve treatment for many patients in the NHS and across the world.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing